Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01823107Not ApplicableCompleted

Feasibility Study of Meso BioMatrix Device for Breast Reconstruction

Role: lead

NCT02309957Completed

EAGLE European Post Market Study

Role: lead

NCT01183637Phase 2Terminated

Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions Pilot Trial

Role: lead

NCT00395785Phase 2Terminated

Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting

Role: lead

All 4 trials loaded